Courtney Moc1, Amy E Taylor1, Gino P Chesini1, Cristina M Zambrano1, Melissa S Barlow1, Xiaoxue Zhang2, Åsa B Gustafsson2, Nicole H Purcell3. 1. Department of Pharmacology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0636, USA. 2. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA. 3. Department of Pharmacology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0636, USA npurcell@ucsd.edu.
Abstract
AIMS: To examine the role of physiological Akt signalling in pathological hypertrophy through analysis of PHLPP1 (PH domain leucine-rich repeat protein phosphatase) knock-out (KO) mice. METHODS AND RESULTS: To investigate the in vivo requirement for 'physiological' control of Akt activation in cardiac growth, we examined the effect of deleting the Akt phosphatase, PHLPP, on the induction of cardiac hypertrophy. Basal Akt phosphorylation increased nearly two-fold in the cardiomyocytes from PHLPP1 KO mice and physiological hypertrophy induced by swimming exercise was accentuated as assessed by increased heart size and myocyte cell area. In contrast, the development of pathophysiological hypertrophy induced by pressure overload and assessed by increases in heart size, myocyte cell area, and hypertrophic gene expression was attenuated. This attenuation coincided with decreased fibrosis and cell death in the KO mice. Cast moulding revealed increased capillary density basally in the KO hearts, which was further elevated relative to wild-type mouse hearts in response to pressure overload. In vitro studies with isolated myocytes in co-culture also demonstrated that PHLPP1 deletion in cardiomyocytes can enhance endothelial tube formation. Expression of the pro-angiogenic factor VEGF was also elevated basally and accentuated in response to transverse aortic constriction in hearts from KO mice. CONCLUSION: Our data suggest that enhancing Akt activity by inhibiting its PHLPP1-mediated dephosphorylation promotes processes associated with physiological hypertrophy that may be beneficial in attenuating the development of pathological hypertrophy. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: To examine the role of physiological Akt signalling in pathological hypertrophy through analysis of PHLPP1 (PH domain leucine-rich repeat protein phosphatase) knock-out (KO) mice. METHODS AND RESULTS: To investigate the in vivo requirement for 'physiological' control of Akt activation in cardiac growth, we examined the effect of deleting the Akt phosphatase, PHLPP, on the induction of cardiac hypertrophy. Basal Akt phosphorylation increased nearly two-fold in the cardiomyocytes from PHLPP1 KO mice and physiological hypertrophy induced by swimming exercise was accentuated as assessed by increased heart size and myocyte cell area. In contrast, the development of pathophysiological hypertrophy induced by pressure overload and assessed by increases in heart size, myocyte cell area, and hypertrophic gene expression was attenuated. This attenuation coincided with decreased fibrosis and cell death in the KO mice. Cast moulding revealed increased capillary density basally in the KO hearts, which was further elevated relative to wild-type mouse hearts in response to pressure overload. In vitro studies with isolated myocytes in co-culture also demonstrated that PHLPP1 deletion in cardiomyocytes can enhance endothelial tube formation. Expression of the pro-angiogenic factor VEGF was also elevated basally and accentuated in response to transverse aortic constriction in hearts from KO mice. CONCLUSION: Our data suggest that enhancing Akt activity by inhibiting its PHLPP1-mediated dephosphorylation promotes processes associated with physiological hypertrophy that may be beneficial in attenuating the development of pathological hypertrophy. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: W S Chen; P Z Xu; K Gottlob; M L Chen; K Sokol; T Shiyanova; I Roninson; W Weng; R Suzuki; K Tobe; T Kadowaki; N Hay Journal: Genes Dev Date: 2001-09-01 Impact factor: 11.361
Authors: F J Giordano; H P Gerber; S P Williams; N VanBruggen; S Bunting; P Ruiz-Lozano; Y Gu; A K Nath; Y Huang; R Hickey; N Dalton; K L Peterson; J Ross; K R Chien; N Ferrara Journal: Proc Natl Acad Sci U S A Date: 2001-05-01 Impact factor: 11.205
Authors: Stephan Schiekofer; Kurt Belisle; Gennaro Galasso; Jochen G Schneider; Bernhard O Boehm; Timo Burster; Gerd Schmitz; Kenneth Walsh Journal: Angiogenesis Date: 2008-05-20 Impact factor: 9.596
Authors: Mark A Lampert; Amabel M Orogo; Rita H Najor; Babette C Hammerling; Leonardo J Leon; Bingyan J Wang; Taeyong Kim; Mark A Sussman; Åsa B Gustafsson Journal: Autophagy Date: 2019-02-22 Impact factor: 16.016
Authors: Bryan S Yung; Cameron S Brand; Sunny Y Xiang; Charles B B Gray; Christopher K Means; Hugh Rosen; Jerold Chun; Nicole H Purcell; Joan Heller Brown; Shigeki Miyamoto Journal: J Mol Cell Cardiol Date: 2016-12-23 Impact factor: 5.000
Authors: Tania Nevers; Ane M Salvador; Anna Grodecki-Pena; Andrew Knapp; Francisco Velázquez; Mark Aronovitz; Navin K Kapur; Richard H Karas; Robert M Blanton; Pilar Alcaide Journal: Circ Heart Fail Date: 2015-05-28 Impact factor: 8.790